Abnormal Striatal Dopamine Transmission in Schizophrenia by Brunelin, Jerome et al.
 
Abnormal Striatal Dopamine Transmission in Schizophrenia
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Brunelin, Jerome, Shirley Fecteau, and Marie-Françoise Suaud-
Chagny. 2013 . “Abnormal Striatal Dopamine Transmission in
Schizophrenia.” Current Medicinal Chemistry 20 (3): 397-404.
doi:10.2174/0929867311320030011.
http://dx.doi.org/10.2174/0929867311320030011.
Published Version doi:10.2174/0929867311320030011
Accessed February 19, 2015 3:03:21 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879382
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAASend Orders of Reprints at bspsaif@emirates.net.ae 
  Current Medicinal Chemistry, 2013, 20, 397-404 397 
 
 
Abnormal Striatal Dopamine Transmission in Schizophrenia 
Jerome Brunelin
*,1,2,3, Shirley Fecteau
3,4 and Marie-Françoise Suaud-Chagny
1,2 
1Université de Lyon; Université Lyon 1, F-69003, Lyon, France; 
2EA4615; CH Le Vinatier, Bron, F-69677, France; 
3Institut Univer-
sitaire en Santé Mentale de Québec (IUSMQ), CIRRIS, Université Laval, Québec, Canada; 
4Berenson-Allen Center for Noninvasive 
Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (MA), USA 
Abstract: Despite numerous revisions and reformulations, dopamine (DA) hypothesis of schizophrenia remains a pivotal neurochemical 
hypothesis of this illness. The aim of this review is to expose and discuss findings from positron emission tomography (PET) or single-
photon-emission computed tomography (SPECT) studies investigating DA function in the striatum of medicated, drug-naïve or drug-free 
patients with schizophrenia and in individuals at risk compared with healthy volunteers.  
DA function was studied at several levels: i) at a presynaptic level where neuroimaging studies investigating DOPA uptake capacity 
clearly show an increase of DA synthesis in patients with schizophrenia; ii) at a synaptic level where neuroimaging studies investigating 
dopamine transporter availability (DAT) does not bring any evidence of dysfunction; iii) and finally, neuroimaging studies investigating 
DA receptor density show a mild increase of D2 receptor density in basic condition and, an hyperreactivity of DA system in dynamic 
condition.  
These results are discussed regarding laterality, sub-regions of striatum and implications for the at-risk population. Striatal DA abnor-
malities are now clearly demonstrated in patients with schizophrenia and at risk population and could constitute an endophenotype of 
schizophrenia. Subtle sub-clinical striatal DA abnormalities in at risk population could be a biomarker of transition from a vulnerability 
state to the expression of frank psychosis. 
Keywords: Dopamine, striatum, schizophrenia, PET; imaging. 
1. INTRODUCTION 
Although undergoing revisions and reformulations, the original 
dopamine (DA) hyperactivity hypothesis of schizophrenia, even 
over about 40 years ago [1] remains a pivotal neurochemical hy-
pothesis increasingly studied in literature (see Fig. (1)). This hy-
pothesis is based on two main observations: 1) it is possible to in-
duce a psychotic episode in healthy subjects with pharmacological 
DA agonist and 2) all effective antipsychotic drug provide at least 
some degree of D2-type DA receptor blockade. The advent in the 
eighties of neuro-imaging techniques based on positron emission 
tomography (PET) or single-photon-emission computed tomogra-
phy (SPECT) opened the possibility of direct investigation of theses 
hypotheses. A hyperactivity of DA systems could be already pre-
sent in the early stage of the illness, before the expression of frank 
psychosis experience and may constitute a biomarker of transition 
from a vulnerability state to full blown episode of schizophrenia. 
Multiple components of dopaminergic neurotransmission may 
cause dopaminergic overactivity, including increased DA synthesis, 
release, receptor number and/or affinity, and DA-mediated postsyn-
aptic effector mechanisms, and decreased inactivation. 
Thanks to methodological advances, certain of these processes 
can now be quantified in vivo in patients, allowing a more compre-
hensive test of the DA overactivity hypothesis than was previously 
available and can test to confirm or refute the hyperDA hypothesis 
in patients with schizophrenia as well as in individuals at risk to 
develop the illness. After giving a brief overview of DA system, 
this paper reviews findings from PET and SPECT studies investi-
gating dopaminergic impairments in patients with schizophrenia 
and in individuals at risk at the presynaptic and synaptic levels, in 
phasic and basal conditions in the striatum.  
2. OVERVIEW OF THE DOPAMINERGIC SYSTEM 
2.1. Anatomy of the DA System 
DA neurons are located in the mesencephalon and project into 
the forebrain along three major pathways forming a complex modu- 
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Fig. (1). Number of original studies and reviews concerning dopamine and 
schizophrenia per decades (NIH Pubmed search with dopamine and schizo-
phrenia as key words, until 2012, July). 
 
 
Fig. (2). Schematic drawing of dopaminergic pathways  
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latory network (see Fig. (2)). The nigrostriatal system is composed 
of DA neurons located in the substantia nigra compacta that project 
into the dorsal striatum. This system is mainly involved in motor 
control. The mesolimbic DA system is composed of neurons lo-
cated in the ventral tegmental area (VTA) that project to limbic 
structures including the nucleus accumbens located into the ventral 
part of the striatum (VS), the basolateral amygdala and the hippo-
campus. Mesolimbic system involving the VS is thought crucial for 
motivation and reward seeking while the DA system involving 
basolateral amygdala and hippocampus is implicated in long-term 
memory and emotion. Finally, the DA mesocortical system is com-
posed of neurons located into the VTA that project to cortical and 
cerebellar areas including the prefrontal cortex (PFC), an area that 
plays a pivotal role in mediating cognitive functions (such as short 
term memory), attention, and executive functions (such as abstract 
reasoning and planning). 
2.2. DA Transmission 
Thanks to animal studies it is now well admitted that DA 
transmission is governed by two signaling modes, a single neuron 
being able to switch from one mode to the other. The tonic mode 
corresponds to a discharge of DA neurons in a low regular spike 
mode (mean firing rate about (4-6 Hz) [2, 3] establishing a steady 
state level of DA efflux responsible for a low basal DA level. 
Change in tonic DA efflux can be too weak to change postsynaptic 
stimulation but sufficient to be involved in homeostatic processes 
such as autoregulation [4]. The phasic signaling corresponds to a 
discharge in a high frequency bursting pattern [3, 5, 6] eliciting 
transient large DA effluxes on top of DA tone [7, 8]. Usually, bursts 
consist of two to six spikes at high frequency (15 Hz-100 Hz) [5, 9]. 
Physiological stimulations such as sensory and appetitive stimuli 
favours bursting activity suggesting that phasic activity convey 
relevant information. The relationship between discharge activity 
and DA release is dependent on various mechanisms including DA 
synthesis and storage, reuptake, metabolism and autoregulation [10, 
11, 12]. DA synthesis occurs within DA neurons from tyrosine 
hydroxylated to L-3.4-dihydroxyphenylalanine (L-DOPA) by tyro-
sine hydroxylase (TH). Upon synthesis, DA arising from L-DOPA 
decarboxylation by aromatic amino acid decarboxylase (AADC) is 
transported into synaptic vesicles by the vesicular monoamine 
transporter (VMAT). In the striatum, re-uptake into DA terminals, 
achieved by DA transporter (DAT), is the main mechanism respon-
sible for the clearance of the released DA [12]. 
In contrast, in the prefrontal cortex DA released is primarily 
metabolized by catechol-O-methyltransferase (COMT) or cleared 
by reuptake into noradrenergic terminals. DA action is mediated via 
five distinct G-protein-coupled receptor subtypes (DA1-DA5). D1-
like receptors (D1, D5) and D2-like receptors (D2, D3 and D4) are 
positively and negatively coupled to adenylate cyclise, respectively. 
D1 receptors are found in DA projection areas while D2 receptors 
are found in DA projection and cell body areas. D2 autoreceptors 
located on DA axonal terminals modulate DA synthesis and release 
(see Fig. 3). 
In a physiopathological context, altogether these results under-
line the importance to consider, beyond the changes in basal ex-
tracellular level, the changes in tonic versus phasic DA signaling 
mode [13]. 
In this way, Grace proposed in schizophrenia an imbalance be-
tween tonic and phasic DA transmission within the ventral striatum 
resulting in a functional impairment in the integration of the infor-
mation convergent from limbic and cortical areas [14]. In schizo-
phrenia, most of the processes involved in DA transmission has 
been used as target in imaging studies. 
 
 
Fig. (3). Schematic drawing of mechanism participating in DA transmission. 
AADC: aromatic amino acid decarboxylase; COMT: catechol-O-
methyltransferase; DA: dopamine; DAT: Dopamine transporter; DOPAC: 
3,4-Dihydroxyphenylacetic acid ; HVA: Homovanillic; L-DOPA: L-3.4-
dihydroxyphenylalanine; MAO: Monoamine Oxydase; TH: tyrosine hy-
droxylase; Tyr: tyrosine; VMAT: vesicular monoamine transporter  
3. RESULTS: DOPAMINEGIC IMPAIRMENTS IN SCHIZO-
PHRENIA 
3. 1.Presynaptic Dopamine Function  
3.1.1. Imaging Measuring DOPA Decarboxylase Activity Indica-
tive of Dopamine Synthesis 
Although it is not possible to measure DA synthesis directly in 
humans, recent neuroimaging provides indirect indices of DA syn-
thesis. A method of imaging presynaptic dopaminergic function 
under baseline conditions measures the formation and storage of 
DA in presynaptic terminals with l-[-11C]DOPA (11C-DOPA) or 
6-[18F]fluoro-L-DOPA (18F-DOPA), 2 radioactive analogues of L-
DOPA, the precursor of DA. The radioactive analogue of DOPA, 
peripherally injected under the scanner, is taken up by presynaptic 
monoaminergic neurons and metabolized by decarboxylase AADC 
to radioactive tagged DA which will be trapped and stored within 
vesicles in the nerve terminals. The uptake of radioactive L-DOPA, 
quantified as the influx constant Ki, measures AADC activity and 
vesicular storage capacity [15] and thus is indicative of DA synthe-
sis capacity. High values for 18F-DOPA Ki are observed in areas of 
dense DA nerve terminal innervation (e.g., the striatum), and 18F-
DOPA uptake correlates with surviving nigrostriatal cell numbers 
in both monkey and human studies [16, 17]. In this way, 18F-
DOPA was extensively used to probe the structural and functional 
integrity of striatal dopaminergic neurons, particularly in Parkinson 
disease and other movement disorders (for review see [18]).  
To date, compared to healthy subjects, elevations of 18F-DOPA 
or 11C-DOPA in the striatum of both antipsychotic-naive and an-
tipsychotic-free patients were observed in the majority of PET stud-
ies [19-25]. Two studies reported different results. One study re-
ported no difference [26] and another one reported reduced 18F-
DOPA striatal uptake in patients as compared to controls [27]. Both 
were conducted in chronic, remitted patients. Finally, a recent meta-
analysis (including 11 different studies from 1994 to 2011), com-
paring 113 patients with schizophrenia and 131 healthy controls 
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reported a relative elevation of on average 14% of dopamine syn-
thesis capacity measured by L-DOPA (11C and 18F) uptake in 
patients in both caudate and putamen [28]. The authors have re-
ported no effect of exposure to antipsychotic medication, illness 
duration, age or intensity of psychotic symptoms. 
Interestingly, 18F-DOPA uptake was also investigated in indi-
viduals at-risk to develop schizophrenia, without experiencing frank 
psychotic symptoms. This target population included unaffected 
first degree relatives of patients with schizophrenia (FDR), indi-
viduals with an At-Risk Mental State (ARMS) for psychosis or twin 
pairs discordant for schizophrenia [29, 30].  
The studying of first degree relatives of patients with schizo-
phrenia [30] revealed that 18F-DOPA uptake was higher in the 
FDR group than in the control group suggesting that the changes of 
striatal presynaptic DA synthesis seen in previous studies in antip-
sychotic-naive and antipsychotic-free patients with schizophrenia 
are also present in FDRs. These findings have implications for the 
early detection of psychosis as well as for pharmacological inter-
ventions in individuals at risk for psychosis. This finding was cor-
roborated in a study of ARMS showing higher 18F-DOPA uptake 
in the associative part of the striatum (AST) of ARMS subjects 
compared to controls [29]. However, another study of ARMS sub-
jects [31] and a study of twin pairs discordant for schizophrenia 
[32] did not confirmed these promising observations and reported 
no difference in 18F-DOPA uptake between at-risk subjects and 
controls. The wide variability between at-risk individuals due to the 
lack of specificity in the features used to characterize the popula-
tions targeted in these studies could explain the discrepancies. For 
example, post-hoc examination of the data corresponding to the 
subjects enrolled in the study of Allen and coworkers who have 
developed psychosis (3 of 20 subjects) [31], indicated that 18F-
DOPA uptake was higher in these 3 ARMS subjects than in the rest 
of the sample. 
Altogether, these results are consistent with a 18F-DOPA up-
take increase in the striatum of patients with schizophrenia as well 
as of subjects with an high risk to develop the pathology. Moreover 
18F-DOPA uptake correlated significantly with severity of prodro-
mal symptom [24]. 
Totally, in schizophrenia and at-risk subjects, imaging data 
suggest an abnormal striatal DA transmission at the presynaptic 
level which can be viewed as an increased DA synthesis capacity. 
From these studies it is not clear if and how the increase in presyn-
aptic DA could account for DA output changes, because measure-
ments depend on AADC activity in a non rate-limitating step of DA 
synthesis. Moreover, because the operating levels of processes in-
volved in intracellular DA storage, such as vesicular transport, are 
missing in schizophrenia, an increase in storage cannot be ruled out.  
3.1.2. Imaging Striatal Dopamine Transporter (DAT) 
The striatal DA transporters (DAT) are located on the presynap-
tic membrane of DA neuron terminals. DAT regulate DA transmis-
sion by removing released DA from the synapse through reuptake. 
The measurement of DAT is usually considered as an index of the 
density of DA terminals or innervation into the striatum. Using 
either PET or SPECT, a lot of studies have examined striatal DAT 
density in antipsychotic-naive and in antipsychotic-free patients 
with schizophrenia. The majority of studies failed to report any 
significant differences between patients and controls [33-37]. A 
recent meta-analysis [38] comparing 202 subjects with schizophre-
nia with 147 matched healthy controls (from 13 independent stud-
ies) did not report evidence indicating altered density of striatal 
dopamine terminals in schizophrenia independently of illness dura-
tion or antipsychotic medication intake. These results suggest that 
the increased presynaptic striatal DA activity in schizophrenia indi-
cated by other imaging parameters is not secondary to dysfunctional 
DAT or an elevation in the density of DA terminals.  
However, some alterations in DAT availability were reported in 
schizophrenia, particularly using SPECT technique. On the one 
hand, DAT availability was found significantly larger (up-
regulation) in chronic schizophrenic patients [39] and in a subgroup 
of patients with predominantly positive symptoms than in controls 
[40]. On the other hand, some studies clearly showed a significant 
decrease of DAT binding in patients with schizophrenia, in young 
antipsychotic-free patients [41] as well as in chronic medicated 
patients [42]. Using recent [123I] FP-CIT tracer, in two independ-
ent studies, Mateos and co-workers [43, 44] reported and confirmed 
that DAT binding was lower in antipsychotic-naive first episode 
patients than in healthy subjects, at baseline and after a 4-week-
treatment period. Interestingly, in a 4-year follow up study, Mané 
and co-workers [45] reported a specific relation between striatal 
DAT number and negative symptoms suggesting that there is a 
close relationship between DAT number and clinical features of 
patients. Finally, supporting abnormal dopamine transmission in 
schizophrenia, using a dual-isotope SPECT technique, a positive 
association between DAT and D2 receptor availability has been 
found in first-episode, antipsychotic-naive patients whereas this 
relation does not exist in controls [35, 37]. 
Altogether, results show many discrepancies. Discrepancies can 
be explained by the heterogeneity in the age range and illness dura-
tion of the samples, the type and length of treatments, the radiotrac-
ers used ([99mTc]TRODAT-1, [18F]CFT or [123I] FP-CIT) , and 
the different methods of quantification applied. Thus, pending fur-
ther replication, most of the evidence at this point does not shows if 
DAT is affected or unaffected in schizophrenia. 
3.2. Synaptic Dopamine Function 
3.2.1. Striatal D2 Receptor Density 
Another approach to measure DA activity in the human stria-
tum consists in measuring DA receptor density through the receptor 
occupancy by a radioligand evaluated by its binding potential. Be-
cause reversibly radioligand competes with endogenous DA for 
receptor binding, it is assumed that radiotracer binding potential is 
indicative of DA level. This measurement is achieved either in ba-
sal or in dynamic conditions. In dynamic conditions, DA release is 
evoked either by the administration of a DA-releasing drug or by 
subjecting individuals to DA-releasing activity such as stress. In 
these conditions, reduction in radiotracer binding potential is 
thought indicative of DA system reactivity by assessing evoked DA 
release. It is undoubtedly because post-mortem studies of D2 recep-
tors in schizophrenia were crucial to the genesis of the DA hypothe-
sis that D2 receptor density has been extensively study in schizo-
phrenia. Dopamine D2-receptor imaging, combined with pharma-
cological manipulation of DA release enables a more direct evalua-
tion of DA presynaptic activity than 18 F-DOPA study. 
In the study of schizophrenia, two imaging techniques are usu-
ally associated with various D2 receptor radiotracers. Among ra-
diotracers available, iodobenzamide (IBZM) and raclopride are the 
most widely used. IBZM is a DA antagonist which is currently used 
as a radioactive tracer for SPECT where the radioactive isotope is 
iodine-123. [123I]IBZM is considered to measure striatal D2 DA 
receptor density. Raclopride is a synthetic compound that acts as an 
antagonist on D2 DA receptors. It can be radiolabelled with the 
carbon-11 radioisotope and used in PET scanning to assess the 
degree of DA binding to the D2/D3 receptors. 
3.2.1.1. Imaging Striatal D2 Receptor Density in Basal Conditions 
Many years ago, increased striatal D2 receptor density was re-
ported [46, 47], but these first findings were questioned on the basis 
that the data were obtained in antipsychotic-treated patients. Indeed, 
classical antipsychotic therapy could, in itself, cause D2 receptor 
upregulation [48, 49]. Imaging studies using PET and SPECT could 
control for this confound by studying never-treated people with 400    Current Medicinal Chemistry,  2013, Vol. 20, No. 3  Brunelin et al. 
schizophrenia. Since these first studies, striatal D2 receptor density 
in schizophrenia has been extensively studied. In a meta-analysis in 
2001, Weinberger & Laruelle [50] have identified 17 imaging stud-
ies using various radiotracers comparing D2 receptors in 245 pa-
tients with schizophrenia (112 antipsychotic naive, 133 antipsy-
chotic free) and matched 231 healthy controls for age and sex. De-
spite only 2 studies (on 17 selected studies) reporting a significant 
elevation of D2 receptor density in patients, the metaanalysis re-
vealed a small but significant global elevation of striatal D2 recep-
tor (12%). The more recent radioligand [18F]fallyprid confirmed 
abnormal D2 receptor density in the striatum of patients with 
schizophrenia [51, 52]. 
However, before any conclusion, it is important to note that 
these findings may be confounded by physiological and methodo-
logical factors. D2 imaging results from several parameters includ-
ing the number of D2 receptors, the ability of the radioligand in 
displacing DA and the level of DA in the vicinity of receptors. 
Moreover discrepancies may result from the radioelement used 
probably because of wide variations in their specific activity and 
thus of competition with endogenous DA. 
Efforts have been made to overcome the problem of a competi-
tion between the radioligand and endogenous DA [53] by develop-
ing D2 imaging in acute DA depletion condition in humans [54, 
55]. Such depletion is achieved by blocking the rate limiting step of 
DA synthesis via orally administering the tyrosine hydroxylase 
enzyme inhibitor, AMPT (Alpha-methyl-p-tyrosine) over 48 h. It is 
assumed that, compared to baseline, the D2 receptor density meas-
ured in the depleted state is extended to D2 receptors occupied by 
endogenous DA at baseline. The unmasked D2 receptor density is 
then considered as an index of DA level at baseline [55]. Using this 
approach with SPECT and the D2 radiotracer [123I]IBZM, Abi-
Dargham and colleagues [56] reported that the increase in D2 re-
ceptor availability after acute DA depletion was significantly larger 
in patients with schizophrenia (during an acute psychotic episode) 
than in controls. Assuming normal affinity of D2 receptor for DA, 
this result was interpreted as an increased occupancy of striatal D2 
receptors by DA at baseline in schizophrenia, and thus as consistent 
with higher DA synaptic levels in patients. It was further noted that 
AMPT exposure led to a significant reduction in severity of positive 
symptoms among patients; the higher occupancy of striatal D2 re-
ceptors by DA the greater was reduction in positive symptoms after 
administration of antipsychotic treatment [56]. 
D2 receptors are highly heterogeneous in various aspects lead-
ing to heterogeneity in their function and response to drug [57]; 
such heterogeneity hampers the interpretation of D2 imaging data. 
Data are interpreted from the hypothesis that D2 affinities are simi-
lar between patients and controls. This hypothesis is questioned by 
the demonstration of the existence of two D2 affinity states for 
agonist binding, DA competing first at high-affinity D2 site coupled 
to G-protein while low affinity D2 site is uncoupled. In vitro studies 
in animal model for psychosis demonstrated an increase in high-
affinity D2 state suggesting that this increase may be responsible of 
DA hyperactivity in schizophrenia [58]. In humans, a specific imag-
ing of each D2 affinity state is still under discussion [59]. The wide 
D2 distribution across constituting neural elements in the striatum 
makes also difficult the functional interpretation of D2 density 
measurements. D2 receptors, existing as long and short variants, are 
distributed across dendritic spines of efferent neurons and interneu-
rons, as well as DA terminals and other terminals such as glutama-
tergic ones. Moreover, the accessibility of D2 receptors depends on 
their localization, synaptically or extrasynaptically, internalized or 
addressed to the membranes. Imaging data do not bring information 
about which D2 receptor population is affected. Finally, in schizo-
phrenia alterations in processes regulating D2 receptors such as an 
impaired D2 trafficking [60] cannot be ruled out. Totally, to date, 
altered D2 receptor binding found in schizophrenia would not sim-
ply indicative of DA level change. 
3.2.1.2. Imaging Striatal D2 Receptor Density in Dynamic Condi-
tions 
Using a Pharmacological Challenge 
The acute DA releasing effect of amphetamine has been dem-
onstrated in schizophrenia by measuring changes in D2 receptor 
availability combined with SPECT and PET [61-63]. The degree of 
amphetamine-induced DA release has been shown dependent on 
patient status in terms of phase of illness and intensity of symp-
toms. When comparing different populations of patients, Laruelle 
and co-workers have observed that, after amphetamine, the sub-
group of schizophrenia patients in the acute phase of illness dis-
played the strongest reduction in striatal [123I]IBZM binding po-
tential. The DA releasing effects of amphetamine were similarly 
large in antipsychotic naïve and previously treated patients experi-
encing exacerbation of positive symptoms whereas the response 
evoked in patients in remission was found lower and not different 
from that of control group [64]. The findings suggest that excessive 
evoked DA release at striatal D2 receptors is involved in the experi-
encing of psychotic symptoms, and highlight a role for a dysregu-
lated, hyperresponsive subcortical DA system that fluctuates in its 
degree of dysregulation during the different phases of the illness.  
More recently, it has been shown that following amphetamine, 
patients with schizotypal personality disorder (SPD) present a 
larger reduction in striatal [123I]IBZM binding potential compared 
to controls that remained, however, lower than that seen in acutely 
ill patients [65]. This result has been replicated in subjects at risk to 
psychosis using other D2 radioligands. An abnormal supra striatal 
DA response has been found after a metabolic stress challenge with 
no direct DA impact in unaffected siblings of patients with schizo-
phrenia [66], after psychosocial stress [67, 68] and also after am-
phetamine challenge in psychometric schizotypal subjects [69]. 
Interestingly, according to the relationship between DA transmis-
sion and stress (for a comprehensive review see [70]), it has been 
shown that the over-DA response evoked by psychosocial stress 
was correlated with salivary cortisol response to stress [68]. 
Taken together, these results suggest that a modest over-
increase in DA release (or a hyperreactivity) may characterize indi-
viduals at risk for psychosis including subjects with spectrum dis-
orders or unaffected relatives and patients between episodes. A high 
degree of DA dysregulation can characterize those reaching the 
threshold of active psychosis including the first episode of the ill-
ness. The hypothesis of an increase DA release in schizophrenia 
and individuals at risk of psychosis is consistent with the data sug-
gesting an increase in DA synthesis (see above). 
The gradation in DA release dysregulation between patients 
with schizophrenia and their unaffected at-risk siblings compared to 
healthy controls has been also confirmed by indirect measures of 
DA activity after a metabolic stress challenge using plasma level 
measurements of homovanillic acid (HVA), a breakdown product 
of DA [71]. Altogether data suggest that DA dysregulation is in-
volved in the process of transition across the stages of illness. How-
ever, according to the modulation of DA activity by other neuro-
transmitters, activity changes, such as hyperactivity in serotonergic 
systems could moderate DA release and thus constitute a protective 
factor against DA hyperactivity in high risk subjects [72]. 
By Acting on Frontal Activity 
Imaging data support the concept of fronto-striatal dysfunction 
in schizophrenia. It has been reported a relationship between dorso-
lateral prefrontal cortex hypoactivity and abnormal striatal 18-F 
DOPA uptake in patients with schizophrenia [19]. Moreover, Kege-
les and co-workers [73] suggest that elevated subcortical dopamine 
function might adversely affect performance of the dorsolateral 
prefrontal cortex in schizophrenia. In the same way, in ARMS indi-
viduals, an abnormal relation has been highlighted between striatal 
L-DOPA uptake and medial temporal lobe [31] and frontal activa-
tions [29], providing additional support for the relation between DA in ST  Current Medicinal Chemistry,  2013, Vol. 20, No. 3      401 
prefrontal dysfunction and potentiated striatal DA activity in the 
illness and its early phase. In this way, schizophrenia could be asso-
ciated to a failure in the inhibitory brake provided by the frontal 
activity on striatal DA system [74]. 
According to the relation between frontal cortex activity and 
ventral striatal DA transmission, striatal DA transmission has been 
investigated using [11C]raclopride displacement following external 
frontal activation in patients with schizophrenia. In this way, it has 
been reported in a young drug naive patient with refractory negative 
symptoms that repetitive transcranial magnetic excitatory stimula-
tion (rTMS) applied over the left DLPFC induced a DA release in 
the ventral striatum (especially on the right ventral striatum; [75]), 
as seen in healthy volunteers [76].  
Before any conclusion, it is important to note that some pa-
rameters which could be confounding at baseline could be also 
confounding in the interpretation of data obtained in dynamic con-
ditions by measuring D2 DA receptor density through the binding 
potential of a radiolabelled antagonist. An increase in D2 affinity 
for DA in schizophrenia cannot be excluded. The development of 
radiolabeled agonist of D2 receptor could settle this issue. 
3.2.2. Striatal D1 Receptor Density 
Compared to studies investigating D2 availability in schizo-
phrenia, fewer studies aimed to investigate D1 receptor density. 
In post-mortem studies only one study has reported lower do-
pamine D1 receptors in the striatum in patients with schizophrenia 
compared to healthy [77] while no significant change has been 
reported in numerous other studies [78,79].  
PET studies using different radiotracers have reported contra-
dictory results showing an unaltered binding potential of D1 recep-
tor over the brain of patients with schizophrenia compared with 
control subjects [80]. When structures were specifically analyzed, 
either a decrease or an increase in D1 receptor density was found in 
the prefrontal and/or striatal regions [81-83]. 
Further studies are needed in order to elucidate the role of stri-
atal D1 receptors in the pathophysiology of schizophrenia. 
3.3. Anatomical and Functional Features 
3.3.1. Striatal Subregions 
The advent of high-resolution PET scanners and the develop-
ment of methods permitting examination of DA receptor parameters 
in the various subregions of the striatum allow to probe aspects of 
DA transmission separately for the functional subdivisions of the 
striatum [84, 85]. Classically, abnormalities in DA system were 
reported in the ventral striatum. Combined with PET and 
[11C]raclopride, studies with high resolution PET have demon-
strated that patients with schizophrenia displayed a significantly 
larger increase in D2 receptor availability after DA depletion com-
pared to controls in the associative striatum (AST), but not in the 
limbic or sensorimotor striatal regions [73]. This result was sup-
ported by measuring DA in response to psychological stress in at 
risk population and in patients [68]. 
Abnormalities in the AST have also been reported using F-
DOPA uptake in ARMS ([29; for a negative result see also [31]),  
These findings have challenged the notion that in schizophre-
nia, alterations in subcortical DA transmission are most promi-
nently localized to the ventral part and highlighted the potential role 
of the AST in the illness. This striatal region receives prominent 
input from the dorso lateral PFC, and is thought to play an impor-
tant role in regulating the circuitry from various cortical regions. 
3.3.2. Lateralisation of Dopamine Abnormalities 
In schizophrenia, dopamine is known to be implicated in func-
tional neuropsychophysiological asymmetry (for a review see [86]). 
McGowan and colleagues [20] as well as Hietala and co-workers  
 
[21] reported that abnormal presynaptic dopamine density (meas-
ured by 6-[18F]-fluorodopa uptake) was lateralised to the left in 
patients with schizophrenia. Other studies have reported a dopa-
minergic asymmetry also in unaffected siblings [30], while no such 
asymmetries were observed in healthy subjects [87]. Strikingly, 
while the majority of PET studies did not report any D2 asymmetry 
in patients, Hirvonen and colleagues [88] noted more pronounced 
D2 increase in left vs. right head of the striatum. The finding that 
unmedicated patients with schizophrenia displayed a left-sided 
spontaneous turning preference (orientating spatial behaviour) that 
was associated with the severity of psychotic symptoms [89] is in 
favor an asymmetrical DA system dysregulation in this population, 
characterized by a more active DA system in the left hemisphere 
which could conceivably be corrected by antipsychotic medication 
[90]. This asymmetry has also been found in dynamic condition. In 
individuals at risk, a stress challenge evokes more DA release in the 
left part of the ventral striatum than in the right part [66]. This ex-
cessive DA release in the left part of the ST was correlated with the 
intensity of positive symptoms. All together, these results suggest a 
pre-existence of abnormal lateralization of DA transmission in the 
early stage of the illness with an excessive left DA transmission 
linked to an excessive DA synthesis.  
In a case report [75], Brunelin and colleagues reported that after 
20 sessions of rTMS applied to the left dorso lateral PFC, the pa-
tient had achieved remission of schizophrenic symptoms. The clini-
cal improvement was accompanied with an induced asymmetrisa-
tion of D2 receptor binding potential in the striatum (Right>Left) 
while no asymmetry was observed in baseline condition in this 
drug-naïve patient. The slight binding potential increase in the right 
ventral striatum measured after TMS regimen suggests an up-
regulation of dopaminergic D2 receptors evoking a change in basal 
dopaminergic transmission. This adaptive mechanism could con-
tribute to a right subcortical dopamine signalization enhancement in 
dynamic/phasic conditions. Further studies are needed to confirm 
this abnormal lateralization of DA systems in schizophrenia. 
CONCLUSION 
In summary, recent studies and meta-analyses have highlighted 
that hyperDA hypothesis in schizophrenia and in at-risk individual 
seem to be a robust result, in terms of presynaptic DA function and 
of evoked DA release by pharmacological-drug or by stress in the 
striatum, probably more pronounced in the left AST.  
DA dysregulation may not be a primary dysfunction in schizo-
phrenia, but rather may represent a final common pathway. The 
aetiology of the striatal dopaminergic dysregulation in schizophre-
nia is still unknown, and evidence support this dysregulation is 
related to numerous alterations in other areas functionally linked, 
such as the frontal cortex and in other neurotransmitter systems that 
regulate DA transmission.  
In addition, as the striatum represents an essential integrative 
node, it seems that DA dysregulation itself may play a role in other 
pathogenic effects. Indeed, the striatum receives inputs from the 
hippocampus and the cortex, two areas involved in the pathology of 
schizophrenia and projects directly and/or indirectly back to the 
cortex and DA midbrain neurons. Striatal dopaminergic dysfunction 
can be also reciprocally linked to a cortical dopaminergic dysfunc-
tion. Acting on the PFC using non invasive brain stimulation tech-
niques permit a subcortical DA release and open the possibility to 
act on abnormal DA transmission in schizophrenia and probably 
from the earliest stages (see [91]).  
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LIST OF ABBREVIATIONS 
AADC  =  Aromatic amino acid decarboxylase  
ARMS  =  At-Risk Mental State for psychosis 
AST =  Associative  striatum   
COMT =  Catechol-O-methyltransferase   
DA =  Dopamine   
DAT  =  Dopamine transporter  
HVA =  Homovanillic  Acid   
IBZM = Iodobenzamide   
L-DOPA =  L-3.4-dihydroxyphenylalanine  
PET  =  Positron Emission Tomography  
PFC =  Prefrontal  cortex   
rTMS  =  Repetitive transcranial magnetic stimulation  
SPECT  =  Single-photon-emission computed tomography  
TH  =  Tyrosine hydroxylase  
VMAT  =  Vesicular monoamine transporter  
VS  =  Ventral striatum  
VTA  =  Ventral tegmental area  
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